NEXI RSI Chart
Last 7 days
-7.2%
Last 30 days
6.0%
Last 90 days
-57.1%
Trailing 12 Months
1013.2%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Nov 22, 2023 | roemer alan s. | sold | -7,758 | 1.9434 | -3,992 | - |
Nov 21, 2023 | roemer alan s. | sold | -8,287 | 2.1621 | -3,833 | - |
Mar 30, 2023 | barer sol j | bought | 164,120 | 0.4103 | 400,000 | - |
Nov 26, 2022 | jones kristi | acquired | - | - | 296,700 | president and ceo |
Nov 22, 2022 | oelke mathias | acquired | - | - | 126,100 | chief science officer |
Nov 22, 2022 | trainer john | acquired | - | - | 125,200 | chief financial officer |
Nov 17, 2022 | barer sol j | bought | 35,917 | 0.4789 | 75,000 | - |
Nov 16, 2022 | barer sol j | bought | 60,300 | 0.4824 | 125,000 | - |
Jun 07, 2022 | verstandig grant | bought | 61,384 | 2.284 | 26,876 | - |
Jun 06, 2022 | verstandig grant | bought | 53,537 | 2.1415 | 25,000 | - |
Which funds bought or sold NEXI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | unchanged | - | 11,038 | 18,266 | -% |
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -38.00 | - | -% |
May 15, 2024 | EPIQ Capital Group, LLC | unchanged | - | 52,966 | 87,651 | 0.04% |
May 15, 2024 | Slate Path Capital LP | unchanged | - | 125,426 | 207,564 | -% |
May 15, 2024 | SABBY MANAGEMENT, LLC | new | - | 335,764,000 | 335,764,000 | 0.19% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -12.27 | 4,866 | 8,864 | -% |
May 15, 2024 | ADAGE CAPITAL PARTNERS GP, L.L.C. | sold off | -100 | -71,160 | - | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -83.48 | -1,000 | 1,000 | -% |
May 13, 2024 | UBS Group AG | unchanged | - | 4.00 | 6.00 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 40.00 | 28.00 | 39.00 | -% |
Unveiling NexImmune, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to NexImmune, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.57 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
NexImmune, Inc. News
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -41.0% | 9.00 | 15.00 | 23.00 | 31.00 | 43.00 | 58.00 | 66.00 | 78.00 | 91.00 | 105 | 115 | 127 | 11.00 |
Current Assets | -47.7% | 5.00 | 10.00 | 19.00 | 25.00 | 37.00 | 52.00 | 60.00 | 72.00 | 86.00 | 99.00 | 111 | 123 | 8.00 |
Cash Equivalents | -64.4% | 3.00 | 9.00 | 16.00 | 22.00 | 35.00 | 46.00 | 41.00 | 25.00 | 30.00 | 37.00 | 64.00 | 118 | 5.00 |
Net PPE | -63.5% | 1.00 | 4.00 | 4.00 | 4.00 | 4.00 | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 |
Liabilities | -19.4% | 5.00 | 6.00 | 6.00 | 7.00 | 11.00 | 10.00 | 10.00 | 8.00 | 7.00 | 7.00 | 5.00 | 6.00 | 27.00 |
Current Liabilities | -18.1% | 5.00 | 6.00 | 6.00 | 7.00 | 10.00 | 9.00 | 9.00 | 7.00 | 7.00 | 7.00 | 5.00 | 6.00 | 27.00 |
Shareholder's Equity | -57.5% | 4.00 | 8.00 | 17.00 | 24.00 | 32.00 | 48.00 | 56.00 | 70.00 | 84.00 | 97.00 | 110 | 120 | - |
Retained Earnings | -2.5% | -222 | -217 | -207 | -199 | -190 | -173 | -158 | -142 | -127 | -112 | -97.57 | -85.39 | -77.58 |
Additional Paid-In Capital | 0.3% | 226 | 225 | 224 | 223 | 223 | 221 | 214 | 213 | 211 | 209 | 207 | 206 | 8.00 |
Shares Outstanding | - | 1.00 | - | 26.00 | 26.00 | - | - | 23.00 | 23.00 | 23.00 | 19.00 | 23.00 | 13.00 | 1.00 |
Float | - | - | - | 6.00 | - | - | - | 29.00 | - | - | - | 298 | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | 19.9% | -5,832 | -7,284 | -6,029 | -12,284 | -11,124 | -11,866 | -11,724 | -16,475 | -11,438 | -9,577 | -13,614 | -11,155 | -7,191 | -6,695 | -6,007 | -6,510 |
Share Based Compensation | -44.5% | 614 | 1,106 | 991 | 842 | 1,478 | 1,437 | 1,309 | 1,646 | 1,670 | 1,628 | 1,483 | 1,197 | 274 | 284 | 340 | 319 |
Cashflow From Investing | -100.0% | - | 3.00 | -5.02 | -42.72 | -143 | 11,937 | 27,902 | 10,619 | 4,004 | -17,195 | -40,034 | -580 | -226 | -248 | -61.39 | 758 |
Cashflow From Financing | - | - | - | - | - | - | 5,145 | - | 33.00 | 504 | 213 | -637 | 124,808 | 10,469 | 4,334 | 7,287 | -4.83 |
Statements Of Operations - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 19,282,230 | $ 47,148,450 |
General and administrative | 13,000,624 | 15,934,439 |
Loss on assets held for sale | 690,768 | 0 |
Total operating expenses | 32,973,622 | 63,082,889 |
Loss from operations | (32,973,622) | (63,082,889) |
Other income (expense), net: | ||
Interest income | 698,395 | 664,372 |
Other expense | (69,166) | (87,682) |
Total other income, net | 629,229 | 576,690 |
Net loss | (32,344,393) | (62,506,199) |
Net loss available to common stockholders’ | $ (32,344,393) | $ (62,506,199) |
Basic net loss attributable to common stockholders per common share (in dollars per share) | $ (30.82) | $ (64.95) |
Diluted net loss attributable to common stockholders per common share (in dollars per share) | $ (30.82) | $ (64.95) |
Basic weighted average number of common shares outstanding (in shares) | 1,049,468 | 962,364 |
Diluted weighted-average number of common shares outstanding (in shares) | 1,049,468 | 962,364 |
Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,202,452 | $ 34,642,340 |
Restricted cash | 20,000 | 55,000 |
Assets held for sale | 1,444,043 | 0 |
Prepaid expenses and other current assets | 734,464 | 2,671,411 |
Total current assets | 5,400,959 | 37,368,751 |
Property and equipment, net | 1,352,901 | 4,459,071 |
Operating lease right-of-use assets, net | 46,716 | 967,032 |
Other non-current assets | 1,793,373 | 264,970 |
Total assets | 8,593,949 | 43,059,824 |
Current liabilities: | ||
Accounts payable | 1,336,318 | 2,377,374 |
Accrued expenses and other current liabilities | 3,679,105 | 7,357,153 |
Operating lease liabilities, current | 68,809 | 599,047 |
Total current liabilities | 5,084,232 | 10,333,574 |
Operating lease liabilities, non-current | 0 | 425,766 |
Total liabilities | 5,084,232 | 10,759,340 |
Commitments and contingencies | ||
Stockholders’ equity | ||
Common Stock, $0.0001 par value, 250,000,000 shares authorized as of December 31, 2023 and 2022, 1,066,320 and 1,043,138 issued and outstanding as of December 31, 2023 and 2022 | 2,646 | 2,608 |
Additional paid-in-capital | 226,101,118 | 222,547,530 |
Accumulated deficit | (222,594,047) | (190,249,654) |
Total stockholders’ equity | 3,509,717 | 32,300,484 |
Total liabilities and stockholders’ equity | $ 8,593,949 | $ 43,059,824 |